Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Beam Therapeutics
Biotech
Beam rejigs deal to retain technology amid partner's dissolution
The planned closure of Bio Palette has triggered the termination of a deal that gave Beam Therapeutics rights to base editing technology.
Nick Paul Taylor
Mar 6, 2026 8:20am
After gene therapy exit, Pfizer licenses Beam gene editing asset
Feb 25, 2026 9:43am
Inside Beam's 'big push' for in vivo gene editing
Jan 21, 2026 7:52am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
Beam gene therapy passes early safety test in AATD
Mar 10, 2025 12:22pm
Beam hits hemoglobin goal in first base editing clinical data
Nov 5, 2024 9:00am
